Risk of Guillain-Barre Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.

ABSTRACT:

Importance

Guillain-Barré syndrome can be reported after vaccination. This study assesses the risk of Guillain-Barré syndrome after administration of recombinant zoster vaccine (RZV or Shingrix), which is administered in 2 doses 2 to 6 months apart.

Objective

Use Medicare claims data to evaluate risk of developing Guillain-Barré syndrome following vaccination with zoster vaccine.

Design, setting, and participants

This case series cohort study included 849 397 RZV-vaccinated and 1 817 099 zoster vaccine live (ZVL or Zostavax)-vaccinated beneficiaries aged 65 years or older. Self-controlled analyses included events identified from 2 113 758 eligible RZV-vaccinated beneficiaries 65 years or older. We compared the relative risk of Guillain-Barré syndrome after RZV vs ZVL,

SUBMITTER: Goud R 

PROVIDER: S-EPMC8561433 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature